UNIVERSITY of MARYLAND
SCHOOL OF MEDICINE



Partner with Us



INDUSTRY PARTNERSHIP HIGHLIGHTS

Notable published collaborations with industry:

Wang, JH, et al., 2025 – J Clin Oncol. 43:2059-68. Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial. DOI: 10.1200/JCO-25-00131.

Simone CB, et al., 2024 – Int J Radiat Oncol Biol Phys. 118:404-14. Multicenter Phase 1b/2a Clinical Trial of Radioprotectant BIO 300 Oral Suspension for Patients With Non-Small Cell Lung Cancer Receiving Concurrent Chemoradiotherapy. DOI: 10.1016/j.ijrobp.2023.08.048.

Ng VY, et al., 2024 – Cureus. 16 :1-18. Results of an Integrated Phase I/II Prospective Clinical Trial (NEXIS) for Neoadjuvant Anti-PDL1 (Durvalumab) and Anti-CTLA-4 (Tremelimumab) With Radiation for High-Risk Soft-Tissue Sarcoma of the Trunk and Extremities. DOI: 10.7759/cureus.72119.

Radiation Oncology

The University of Maryland School of Medicine's Department of Radiation Oncology is **a leader in cutting-edge cancer research and care,** offering advanced modalities (e.g. proton therapy, GammaPod® breast-SBRT) and robust translational programs. As part of the NCI-designated Greenebaum Comprehensive Cancer Center (UMGCCC), we have an established **history of industry collaboration on novel therapies and technologies.** Our investigators have created FDA-approved devices (e.g. GammaPod) and secured major NIH funding for projects like FLASH radiation therapy. These assets, combined with a large, diverse patient population and **a full spectrum of radiation platforms,** make us an ideal partner for biopharmaceutical R&D companies.

Preclinical & Translational Development Assets

ROBIN OligoMet Center: Focusing on radiation effects in oligometastatic prostate cancer.

Division of Translational Radiation Sciences: Features a network of research laboratories focusing on areas such as: chromatin/DDR studies, TP53/radiosensitization, DNA damage/repair in leukemia, and GPCR signaling.

FLASH Research Program: Multi-modality FLASH RT platform (electron and proton) devoting approximately $1.8M departmental funding in 2020; preclinical models and imaging studies to accelerate ultra-high-dose-rate therapy development.

Medical Physics Labs: Dedicated to AI/image-guidance work including virtual physics phantoms and proton prompt-gamma imaging.

Clinical Development Capabilities

NCI-Designated UMGCC: The Department of Radiation Oncology is an integral contributor to team science and high-profile clinical trials at the UMGCCC. Multidisciplinary tumor boards and rapid accrual are institutional strengths.

Advanced Modalities: Full portfolio including image-guided external-beam RT, SBRT/SRS, FDA-cleared GammaPod™ breast SBRT, high-dose-rate brachytherapy, and clinical hyperthermia. These capabilities facilitate specialized trials (e.g. dose-escalation, re-irradiation).

Proton Therapy: Maryland Proton Treatment Center (MPTC) operates in partnership with the UMGCCC and provides access to pencil-beam scanning protons. It is a top 10 national enrollment site in proton trials.

The Future of Medicine is Collaboration

> > >

Clinical Development Capabilities *continued*

Trial Accrual: Exceptional enrollment capacity, dedicated research staff, and diverse community sites (Columbia, Baltimore–Washington, Upper Chesapeake, Shore, Capital Region) enable broad patient access. UMGCCC is consistently recognized as a top-accruing site for NRG Oncology trials.

Innovations in Care: Exemplar innovations in care include: GammaPod breast SBRT invented at UMD (first clinical use in 2017) and ongoing device trials; advanced imaging (4D-CT, onboard MRI) for motion management.

HEOR and Post-Approval Capabilities

Real-World Evidence: Including EHR and health care claims. Racially and ethnically **diverse 2.3 million patient health system** and community engaged research methodologies.

Advanced analytics: Including large language model development.

WE WELCOME PARTNERSHIP DISCUSSIONS

Our clinicians and researchers are eager to translate new ideas into trials. We invite industry partners to leverage our integrated clinical network, state-of-art facilities, and scientific expertise to accelerate innovation in radiation oncology. Contact us to explore collaboration opportunities in areas including:

• Radiation + Drug Development: Early-phase trials of novel radiosensitizers (small molecules, immunomodulators, radiopharmaceuticals) and adaptive combination regimens.
• Technology & Device Innovation: Co-development of next-gen platforms (FLASH-capable systems, image-guidance algorithms, wearable/risk-predicting sensors) and radiation delivery tools.
• Biomarker & Genomics: Radiation-specific biomarker discovery (circulating DNA/RNA, immune correlates), patient stratification for precision radiotherapy, and companion diagnostic development.
• Digital Health & AI: Partnerships to create AI-driven treatment planning/decision support, predictive analytics (dose-response models, toxicity predictors), and tele-radiation solutions.
• Outcomes & RWE Research: Joint real-world evidence studies (comparative effectiveness of modalities, long-term outcomes) using our large EMR and claims-linked databases.

Let's discuss collaborating, contact:

Martha Jurczak, MFA
Assistant Dean for Business and Economic Development
MJurczak@som.umaryland.edu
www.medschool.umaryland.edu